On Wednesday, Anheuser Busch Inbev SA (ADR)(NYSE:BUD)’s shares inclined 0.06% to $107.88.
Anheuser-Busch InBev (AB InBev) (BUD) notes the declarement made by SABMiller plc. AB InBev confirms that it has made an approach to SABMiller’s Board of Directors regarding a combination of the two companies. AB InBev’s intention is to work with SABMiller’s Board toward a recommended transaction.
There can be no certainty that this approach will result in an offer or agreement, or as to the terms of any such agreement.
A further statement will be made as appropriate.
In accordance with Rule 2.6(a) of the City Code on Takeovers and Mergers (the “Code”), AB InBev must, by not later than 5.00 p.m. on Wednesday 14 October, 2015, either declare a firm intention to make an offer for SABMiller in accordance with Rule 2.7 of the Code or declare that it does not intend to make an offer for SABMiller, in which case the declarement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline will only be extended with the consent of SABMiller and the Takeover Panel in accordance with Rule 2.6(c) of the Code.
Anheuser-Busch InBev SA/NV, a brewing company, engages in the production, distribution, and sale of beer, alcoholic beverages, and soft drinks worldwide. It offers a portfolio of about 200 beer brands, which comprises Budweiser, Corona, Stella Artois, Beck’s, Leffe, Hoegaarden, Bud Light, Skol, Brahma, Antarctica, Quilmes, Victoria, Modelo Especial, Michelob Ultra, Harbin, Sedrin, Klinskoye, Sibirskaya Korona, Chernigivske, Cass, and Jupiler. Anheuser-Busch InBev SA/NV was founded in 1366 and is headquartered in Leuven, Belgium.
AstraZeneca plc (ADR)(NYSE:AZN)’s shares dropped -0.03% to $32.29.
AstraZeneca will present 33 abstracts from across the respiratory disease portfolio at the 2015 European Respiratory Society (ERS) meeting in Amsterdam, Netherlands, 26-30 September. Data will comprise results from AstraZeneca’s growing inhaled portfolio of LAMA/LABA therapies, as well as findings from the company’s biologics pipeline and early science programs.
Maarten Kraan, Vice President, Respiratory, Inflammation and Autoimmune Therapy Area, said: “The data presented at ERS further demonstrate the diversity of AstraZeneca’s portfolio of innovative formulations and devices which provide physicians with the opportunity to select the right therapy to meet their patients’ needs recently and in the future.”
Data from growing inhaled respiratory portfolio reinforce importance of delivering combination therapies in a single device
Among key abstracts being presented at ERS are the positive Phase III safety and efficacy data for PT003, the investigational therapy combining glycopyrrolate and formoterol fumarate in a pressurized metered dose inhaler (pMDI).
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its products comprise Crestor for dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders; Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium to treat acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients.
At the end of Wednesday’s trade, HCP, Inc. (NYSE:HCP)‘s shares surged 0.68% to $38.56.
HCP (HCP), in recognition of its sustainability achievements, has been named to the Dow Jones Sustainability North America Index for the third successive year, and has achieved constituency for the first time in the Dow Jones Sustainability World Index.
The Dow Jones Sustainability Index Series represents industry leaders that outperform their peers in sustainability metrics based on an analysis of financially material economic, environmental, and social factors. Constituency in the North America Index is awarded to the top 20% of the 600 largest North American companies in the S&P Global Broad Market Index, and constituency in the World Index is awarded to the top 10% of the 2,500 largest companies in the S&P Global Broad Market Index.
HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. It primarily invests in properties serving the healthcare industry counting sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing.
GlaxoSmithKline plc (ADR)(NYSE:GSK), ended its Wednesday’s trading session with 0.01% gain, and closed at $38.83.
GlaxoSmithKline plc GSK) and Theravance, Inc. (THRX) recently initial results from the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) for Relvar®/Breo® Ellipta® 100/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’). The study involved 16,485 patients from 43 countries who had chronic obstructive pulmonary disease (COPD) with moderate airflow limitation (FEV1 50-70% predicted) and either a history or raised risk of cardiovascular disease (CVD).
For the primary endpoint of the study, the risk of dying on FF/VI 100/25mcg was 12.2% lower than on placebo* over the study period, which was not statistically noteworthy(p=0.137).
For the first of two secondary endpoints, FF/VI 100/25mcg reduced the rate of lung function decline (as measured by forced expiratory volume in one second, ‘FEV1’) by 8mL per year contrast with placebo (p=0.019). As the primary endpoint was not met, statistical significance cannot be inferred from this result. For the other secondary endpoint, the risk of experiencing an on-treatment cardiovascular (CV) event (CV death, myocardial infarction, stroke, unstable angina and transient ischemic attack [TIA]) at any time was 7.4% lower in patients taking FF/VI 100/25mcg as compared to placebo which was not statistically noteworthy(p=0.475).
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, counting vaccines, over-the-counter medicines, and health-related consumer products worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
